P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies

• Stuart K. Roberts,
• Curtis L. Cooper,
• Eric Lawitz,
• K. Rajender Reddy,
• Alex J. Thompson,
• Stefan Zeuzem,
• Ira M. Jacobson,
• Peter Ruane,
• Robert H. Hyland,
• Luisa M. Stamm,
• Lingling Han,
• Diana M. Brainard,
• Norbert Bräu,
• Tarik Asselah,
• Bernard E. Willems,
• Steven Flamm,
• Marc Bourlière,
• Graham R. Foster,
• Edward J. Gane,
• Michael Manns,
• Stuart C. Gordon,
• Kris Kowdley

Affiliations

Stuart K. Roberts

Alfred Hospital, Melbourne, Australia

Curtis L. Cooper

Ottawa Hospital Research Institute, Canada

Eric Lawitz

Texas Liver Institute, University of Texas Health Science Center, San Antonio

K. Rajender Reddy

University of Pennsylvania, Philadelphia, US

Alex J. Thompson

St. Vincent's Hospital, Melbourne, Australia

Stefan Zeuzem

Johann Wolfgang Goethe University Medical Center, Frankfurt, Germany

Ira M. Jacobson

Mount Sinai Beth Israel, New York

Peter Ruane

Ruane Medical and Liver Health Institute, Los Angeles

Robert H. Hyland

Gilead Sciences, Inc, Foster City

Luisa M. Stamm

Gilead Sciences, Inc, Foster City

Lingling Han

Gilead Sciences, Inc, Foster City

Diana M. Brainard

Gilead Sciences, Inc, Foster City

Norbert Bräu

Mount Sinai School of Medicine, New York, US

Tarik Asselah

Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM UMR1149, Université Paris Diderot, Clichy, France

Bernard E. Willems

Centre Hospitalier de l’Université de Montréal, Canada

Steven Flamm

Northwestern University, Chicago, US

Marc Bourlière

Hospital Saint Joseph, Marseille, France

Graham R. Foster

Royal London Hospital, UK

Edward J. Gane

Auckland Clinical Studies, New Zealand

Michael Manns

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany

Stuart C. Gordon

Henry Ford Health System, Detroit

Kris Kowdley

Swedish Medical Center, Seattle, USA